Virtual Library
Start Your Search
J. Rodrigues
Author of
-
+
P1.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 692)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.06-010 - Interaction between Treatment Delivery Delay and Stage on the Mortality from Non-Small Cell Lung Cancer (ID 9093)
09:30 - 09:30 | Author(s): J. Rodrigues
- Abstract
Background:
Objective: The aim of this study is to evaluate the effect on the mortality of a delay of more than 2 months in treatment delivery after the diagnosis of non small cell lung cancer (NSCLC).
Method:
We performed a retrospective review of records form patients registered in a prospectively keep database on lung câncer.. patients with malignant lung neoplasms, admitted at a single reference oncology center of public-system health between July 2008 and December 2014. Patients were considered eligible for this study if they were older than 18 years and had not undergone any previous oncology treatment when they were admitted at the institution. The following data were collected from all patients: age, gender, smoking status, histological type, surgical treatment, tumor staging and time from the date when the patient was diagnosed with cancer to the starting date of effective treatment.
Result:
We identified 359 elegible patients. Of these, 278 (77.4%) died during follow-up while 81 (22.6%) were censored. Age, sex and smoking status were not statistically significant predictors of mortality and were not considered for multivariate analysis. Stage of disease, surgical treatment and histological type of lung cancer were predictor of mortality (p< 0.05)). Besides that, in both the crude and adjusted analysis, delayed delivery of treatment was protective for the risk of death, with a crude HR= .75 (.59 - .97; p= .02) and an adjusted HR= .59 (.46 - .77; p<.001). A statistically significant interaction for mortality was observed between timely delivery of treatment and tumor stage (p=.01). The HR for mortality of getting delayed access to treatment according to stage are described: stages I and III, mortality was not significantly different between those that got treatment before or after 2 months from diagnosis (Stage I: HR= 1.24 (.39 – 3.98; p=.71); Stage III: HR= .65 (.38 – 1.1; p=.11)). However, patients with stage II disease who received delayed treatment had a mortality 3 times higher than those that received timely treatment delivery (HR= 3.08 (1.05 – 9.0; p=.04)). On the other hand, stage IV patients that received delayed treatment had a 52% reduction in mortality.
Conclusion:
There was influence of stage at the association between time to start treatment and mortality. About this influence, only the subgroup of stage II NSCLC patients appears to benefit of early treatment.
